ProMIS Q3 net income $9.3M, cash $21.5M; Phase 1a positive; PIPE up to $122.7M

ProMIS Neurosciences Inc.

2024-Q3 EPS reported $0.13

Net income of $9.3M for Q3 2024 vs net loss of $2.4M YoY, driven by $17.0M gain on warrant liabilities.
Cash and equivalents $21.5M at Sep 30, 2024, up from $12.6M at Dec 31, 2023.
PIPE financing closed with initial $30.3M; potential additional $92.4M from warrant exercise.
Phase 1a trial of PMN310 in Alzheimer's showed good tolerability, dose-dependent BBB crossing, supporting monthly dosing.
Phase 1b clinical trial in AD patients on track to start by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.